What is new?
February 7, 2020
Most Recent
From: January 2020 Edition of Pediatric Physical Therapy journal:
CINCINNATI—Julie Badylak PT and Rebecca Durham Reder OTD, OTR/L from Cincinnati Children’s Hospital discuss the findings of their team’s report in the journal Pediatric Physical Therapy on the assessment of tasks …
Audio Journal of Oncology
Reporting from 2018 annual meeting of the American Society of Hematology
SAN DIEGO—Individualized therapy decisions that are founded on “genomic fingerprint” data can now be made within seven days for most patients with suspected diagnoses of …
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …
MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and …
MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two …
MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib …
MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …
MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 …
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and …
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 …
MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast …
MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo …
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
